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Abstract
The noradrenergic locus coeruleus (LC) is the principal source of brain norepinephrine, a neurotransmitter
thought to play a major role in the pathology of major depressive disorder (MDD) and in the therapeutic
action of many antidepressant drugs. The goal of this study was to identify potential mediators of brain
noradrenergic dysfunction in MDD. Bone morphogenetic protein 7 (BMP7), a member of the transforming
growth factor-b superfamily, is a critical mediator of noradrenergic neuron differentiation during
development and has neurotrophic and neuroprotective effects on mature catecholaminergic neurons.
Real-time PCR of reversed transcribed RNA isolated from homogenates of LC tissue from 12 matched
pairs of MDD subjects and psychiatrically normal control subjects revealed low levels of BMP7 gene
expression in MDD. No differences in gene expression levels of other members of the BMP family were
observed in the LC, and BMP7 gene expression was normal in the prefrontal cortex and amygdala in MDD
subjects. Laser capture microdissection of noradrenergic neurons, astrocytes, and oligodendrocytes from
the LC revealed that BMP7 gene expression was highest in LC astrocytes relative to the other cell types,
and that the MDD-associated reduction in BMP7 gene expression was limited to astrocytes. Rats exposed
to chronic social defeat exhibited a similar reduction in BMP7 gene expression in the LC. BMP7 has unique
developmental and trophic actions on catecholamine neurons and these findings suggest that reduced
astrocyte support for pontine LC neurons may contribute to pathology of brain noradrenergic neurons
in MDD.
Received 5 May 2011 ; Reviewed 6 June 2011 ; Revised 24 June 2011 ; Accepted 1 August 2011 ;
First published online 6 September 2011
Key words : Astrocyte, bone morphogenetic protein, glia, locud coeruleus, major depression,
noradrenergic, suicide.
Introduction
Major depressive disorder (MDD) is a psychiatric
illness affecting 13–14 million people in the USA
annually (Kessler et al. 2003). Modern treatment for
depression began in the 1950s and was followed by
decades of research to develop better antidepressant
drugs. Unfortunately, many newer antidepressants do
not demonstrate a significantly greater therapeutic ef-
ficacy than the older drugs, although some exceptions
have been noted (Montgomery et al. 2007; Papakostas
et al. 2007). Inadequate or incomplete treatment of the
disorder remain major health and economic issues
(Thase, 2009). It is widely believed that improved
pharmacological management will follow from a more
thorough understanding of the pathobiology of the
illness. Research dedicated to this cause has revealed a
complex disorder of brain biology, including abnor-
malities in neurotransmitters, stress hormones, neuro-
trophic factors, and an involvement of glia (Banasr &
Duman, 2007 ; Duman &Monteggia, 2006 ; Krishnan &
Nestler, 2008; Rajkowska & Miguel-Hidalgo, 2007).
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Of neurotransmitter systems that demonstrate
abnormalities in MDD, the brain noradrenergic
system has received considerable attention. Short-term
depletion of catecholamines by administration of
a-methyl-p-tyrosine to psychiatrically and medically
healthy subjects did not significantly affect mood
(Salomon et al. 1997). However, rapid pharmacological
depletion of catecholamines in patients taking nor-
adrenergic antidepressants caused a rapid relapse of
depression (Charney, 1998), and catecholamine de-
pletion in unmedicated, fully remitted subjects with
histories of MDD resulted in relapse into depression
(Berman et al. 1999). These demonstrations of a
prominent role of norepinephrine in the behavioural
biology of depression are supported by several studies
demonstrating pathology of the major neuronal source
of brain norepinephrine, the locus coeruleus (LC) in
depressive subjects (for review, see Ordway, 2007).
Given the body of literature suggesting that de-
creased expression of neurotrophic factors contribute
to depression (Duman &Monteggia, 2006), we became
interested in the possibility of a link between de-
pression and trophic factors specifically involved in the
development and growth of norepinephrine neurons.
Bone morphogenetic proteins (BMPs) are a family
of growth factors first discovered in bone, but are also
expressed in the brain where they are involved in
many aspects of the differentiation and morphogen-
esis of neurons and glia. Of BMPs, BMP7, a member of
the transforming growth factor-b (TGF-b) superfamily,
is of particular interest because it plays a major role in
the development of noradrenergic neurons. For ex-
ample, a deletion mutation of BMP7 and BMP5 genes
results in an absence of noradrenergic neurons in the
LC (Tilleman et al. 2010). In addition, BMP7 has
neurotrophic and neuroprotective effects on mature
catecholaminergic neurons. For example, BMP7 in-
duces dendritic growth of noradrenergic neurons
(Lein et al. 1996, 2002a) and protects noradrenergic
neurons from 6-hydroxydopamine-induced neuro-
toxicity (Harvey et al. 2004). BMP7 is down-regulated
following catecholamine neuron lesions (Chen et al.
2003), suggesting a reciprocal regulatory link between
BMP7 and catecholamines.
Because of its specific developmental and trophic
effects on catecholamine neurons, it is conceivable that
a deficit of BMP7 could contribute to disrupted nor-
adrenergic signalling inMDD, or alternatively, reduced
noradrenergic signalling could elicit a change in the
expression of BMP7 or its receptors. Hence, in the
present study we investigated the possibility that
BMP7 gene expression may be altered in MDD. BMP7
gene expression levels were first measured in the
noradrenergic LC dissected from post-mortem brain-
stems of MDD subjects and psychiatrically normal
control subjects. After discovering low levels of BMP7
gene expression in MDD subjects, additional studies
examined gene expression levels of several other
BMPs in LC tissue, and examined whether reduced
BMP7 gene expression was found in other brain re-
gions. Laser capture microdissection (LCM) was em-
ployed to determine which type of cell in the LC
exhibited a deficit in BMP7 gene expression in MDD.
Finally, a social stress paradigm in rats (chronic social
defeat) was used to examine the possibility that stress,
a known precipitator of depression in humans (Paykel
et al. 1969), might regulate BMP7 gene expression. The
findings presented here demonstrate for the first time
that astrocytes closely associated with norepinephrine
neurons are abnormal in MDD, and suggest that
trophic support of norepinephrine neurons by these
glial cells may be deficient in MDD.
Method
Human brain tissues
Post-mortem human brain tissue was collected at
autopsy at the Cuyahoga County Coroner’s Office in
Cleveland, Ohio, in accordance with an approved
Institutional Review Board Protocol, as described
previously (Karolewicz et al. 2005). One MDD subject
was also obtained courtesy of Dr Gustavo Turecki,
from the Quebec Suicide Brain Bank at the Douglas
Hospital Research Center under an approval of the
Douglas Hospital Research Center’s Research Ethics
Committee. Retrospective, informant-based psychi-
atric assessments were performed for all depressed
and control subjects as described previously (Dumais
et al. 2005; Stockmeier et al. 2002) using standardized
questionnaires modified for psychological autopsy.
Axis I psychopathologies were assessed and consen-
sus diagnoses were reached in conference using in-
formation from the interview and medical records.
Blood and urine samples from all subjects were exam-
ined for psychotropic medications and substances of
abuse. Subjects with antidepressant or antipsychotic
drugs in their post-mortem toxicology and/or with
alcohol dependence (current and/or historical) were
excluded from the study.
Brain tissues from a total of 19 psychiatrically nor-
mal control subjects and 19 subjects with MDD were
obtained (see Table 1). Control subjects had no Axis I
psychiatric diagnosis at the time of death except
nicotine dependence and one subject that had a
specific phobia (situational). Control subjects also had
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no known substance abuse disorder except nicotine
dependence and one subject that had a history of mild
alcohol dependence but was in sustained remission at
the time of death (number of years of remission
unknown). Three subjects in the control group had
alcohol in their blood, but none of these subjects had a
Table 1. Subject demographics and tissue use
Group/subject Age, yr Sex pH RIN PMI Smoker Toxicology Assays Tissue
Normal control subjects
A-1 82 M 6.72 6.7 16 No NDD rtPCR Amyg
BB1 52 M 6.28 6.4 17 No NDD rtPCR LC, Ctx, Amyg
RR 37 M 6.47 7.3 17 No NDD rtPCR LC, Ctx, Amyg
VV 54 M 6.52 7.7 19 Yes Lidocaine rtPCR LC, Ctx
HH1 54 M 6.87 6.6 17 No ; hx 10 yra Brompheniramine rtPCR LC, Ctx
FF1 27 M 6.88 8.4 17 Yes NDD rtPCR, LCM LC, Ctx, Amyg
KS6 43 M 6.58 7.4 22 No NDD rtPCR LC, Ctx
KS19 46 F 6.86 6.8 9 Yes NDD rtPCR LC
KS21 48 M 6.98 7.40 9 Yes NDD rtPCR, LCM LC, Ctx
KS23 58 M 6.78 7.7 21 Yes NDD rtPCR, LCM LC, Ctx
KS27 74 M 6.62 6.7 21 Yes NDD rtPCR LC, Ctx
KS31 59 M 6.79 7.6 6 No, hx Lidocaine rtPCR, LCM LC, Ctx, Amyg
KS34 23 F 6.84 6.9 11 No NDD rtPCR LC, Ctx
KS39 34 M 6.61 7.9 24 No Ethanol (0.02)b rtPCR Amyg
KS43 67 M 6.96 8.1 24 Yes NDD rtPCR Amyg
KS57 17 M 6.71 7.4 24 No Ethanol LCM LC
KS59 46 M 6.95 7.0 19 No Ethanol (0.03) rtPCR, LCM LC, Ctx, Amyg
KS63 18 M 6.40 6.4 31.5 Unknown Midazolam rtPCR LC
KS-65 58 M 5.8 6.4 27 No NDD rtPCR LC
Major depressive subjects
H 73 M 6.59 6.6 17.5 No Diazepam, codeine rtPCR Amyg
DD1 52 M 6.48 5.8 18 No CO rtPCR LC, Ctx, Amyg
TT 38 M 6.52 7.2 24 No NDD rtPCR LC, Ctx, Amyg
WW 65 M 6.24 6.7 30 Yes Codeine rtPCR LC, Ctx
JJ1 54 M 6.24 6.3 23 No, hx 30 yr CO rtPCR LC, Ctx
GG1 30 M 6.91 8.0 18 Yes NDD rtPCR, LCM LC, Ctx, Amyg
KS8 42 M 6.67 6.7 44 No NDD rtPCR LC, Ctx
KS17 45 F 6.84 6.6 27 Yes NDD rtPCR LC
KS12 41 M 6.24 6.70 19 Yes Chlorpheniramine rtPCR, LCM LC, Ctx
KS24 64 M 6.85 7.25 26 Yes Ethanol rtPCR, LCM LC, Ctx
KS28 81 M 6.78 6.1 33 Yes NDD rtPCR LC, Ctx
KS32 60 M 6.32 6.80 20 Yes Ethanol rtPCR, LCM LC, Ctx, Amyg
KS35 36 F 6.84 7.5 25 Yes NDD rtPCR LC, Ctx
KS38 38 M 6.80 7.7 20 Yes NDD rtPCR Amyg
KS42 42 M 6.47 6.7 20 Unknown NDD rtPCR Amyg
KS56 37 M 6.67 6.90 31 No Ethanol rtPCR, LCM LC, Ctx, Amyg
KS58 18 M 6.58 6.83 27 Unknown CO rtPCR, LCM LC
KS64 20 M 6.73 6.7 20 No Diphenhydramine rtPCR LC
KS66 48 M 6.68 6.7 17 No NDD rtPCR LC
Summary data
Control subjects 47¡4 17M/2F 6.7¡0.1 7.2¡0.1 19¡1
MDD subjects 47¡4 17M/2F 6.6¡0.1 6.8¡0.1 24¡2c
RIN, RNA integrity number ; PMI, post-mortem interval ; NDD, no drugs detected; rtPCR, real-time PCR performed on punched
LC tissue ; LCM, end-point PCR performed on cells captured by laser capture microdissection ; LC, locus coeruleus ; Ctx, cortex
BA 10 ; Amyg, basal amygdaloid nucleus.
a History with years since (when known).
b Blood ethanol in g/dl.
c Significantly different from control group, p<0.05.
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current or historical alcohol dependence or abuse.
Control subjects died as a result of heart disease
(10 subjects), motor vehicle accident (three subjects),
homicide (one subject), thrombophlebitis (one sub-
ject), aneurism (two subjects), bronchial asthma (one
subject), and acute haemorrhagic pancreatitis (one
subject). Subjects in the MDD group had no known
substance abuse disorder except for nicotine depen-
dence, two subjects who had active alcohol abuse, and
one who had a history of alcohol abuse. The MDD
subjects included one who had comorbid panic
disorder with agoraphobia and a specific phobia
(situational), one who had a comorbid learning dis-
order (not otherwise specified), and two who had a
comorbid dysthymic disorder. Five of the 19 MDD
subjects had a history of antidepressant drug pre-
scriptions (fluoxetine, paroxetine, sertraline, trazo-
done) in medical records, but none of these subjects
demonstrated positive toxicology for these drugs at
autopsy, indicating non-compliance to medication or
termination of compliance prior to death. Medication
history of one of the MDD subjects was unknown.
Most of the MDD subjects died by suicide (nine self-
inflicted gunshot wounds, three carbon monoxide
poisonings, one hanging, one drowning, one asphyxi-
ation, one overdose with unknown substance), while
the remainder died of other causes including heart
disease (two subjects), and pulmonary thromboem-
bolism (one subject). Post-mortem toxicology, age,
gender, and tissue-related factors are given in Table 1.
All of the demographic details of individual subjects,
including causes of death and comorbidities, are
not aligned in Table 1 in order to protect subject
identities. The pairing of normal control and MDD
subjects listed in Table 1 for each set of experiments in
figures can be found in Supplementary Table S1
(available online).
Tissue preparation and sectioning
Blocks of tissue containing the pontine LC, right pre-
frontal cortex (Brodmann area 10), and the basal
nucleus of the amygdala were frozen at autopsy and
stored at x80 xC. Tissue blocks were sectioned with a
cryostat microtome (Leica CM3050 S). Unmounted
frozen sections containing the LC were punched with
a 5-mm diameter trephine (Fig. 1) for real-time PCR
(rtPCR; 3r50 mm sections) experiments involving
the LC. Equivalent rostro-caudal levels along the axis
of the LC within a region 7–10 mm caudal to the
frenulum were determined as described previously
(Karolewicz et al. 2005). For prefrontal cortex, 10 frozen
sections (50 mm) were cut for each subject so that col-
lected tissue contained all six layers of cortex and
minimal white matter. For amygdala, a 3-mm trephine
was used to punch the magnocellular portion of the
basal nucleus of the amygdala from three sections
(50 mm) per subject as previously described (Xiang
et al. 2008). Sections (10 mm) for LCM were mounted
on a room-temperature (22 xC) HistoGene1 LCM
microslide (Molecular Devices, USA) and placed
immediately in a chilled microslide box on dry ice in
a desiccator. Before sectioning and between each
tissue block, the knife-holder and anti-roll plate were




Fig. 1. Images of tyrosine hydroxylase immunostains of two adjacent sections cut through a block of tissue within the human
pons illustrating the dissection of tissue containing the locus coeruleus (LC) (only the right side nucleus is shown in each image).
The arrow labelled LC points to the central region of the LC. Neuromelanin-containing noradrenergic neurons were collected by
LCM from the dark cell-dense region. The white line encompasses the region of the LC including its dendritic expanse where
oligodendrocytes and astrocytes were collected by LCM. The right panel shows the adjacent stained section after LC tissue was
punch-dissected with a 5-mm trephine for real-time PCR experiments on LC homogenates. The punched region of the LC
contained the cell bodies of noradrenergic neurons, glia, and surrounding neuropil under the influence of norepinephrine,
including norepinephrine released in the dendritic field of the LC (Pudovkina et al. 2001). SCP, Superior cerebellar peduncle.
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Staining
Frozen tissue sections containing LC neurons were
stained using the HistoGene1 LCM Frozen Section
Staining kit (Molecular Devices) as described pre-
viously (Ordway et al. 2009). Oligodendrocytes were
stained using a modified Nissl staining protocol and
staining for astrocytes was performed by rapid GFAP
immunocytochemistry, both as described previously
(Ordway et al. 2009). Staining for tyrosine hydroxylase
immunoreactivity was performed as described pre-
viously (Ordway et al. 1997).
Staining for BMP7 and BMPRII immunoreactivity
was performed using formalin-fixed, paraffin-
embedded pontine tissue that was sectioned onto
glass slides using a microtome. Paraffin was removed
from the tissue with xylene. Subsequently, tissue sec-
tions were passed through decreasing ethanol con-
centrations and rehydrated with water. Sections were
then boiled in a 1:10 dilution of Citra Plus (BioGenex,
USA; HK080–9K) in a microwave for 12 min, cooled
for 20 min, washed in deionized H2O three times for
5 min, and rinsed four times for 10 min with PBS.
Endogenous peroxidase activity in the tissue was
neutralized in 3% H2O2 in PBS (pH 7.4) for 10 min.
After blocking with 10% normal goat serum in PBS
with 0.3% Triton-X 100 for 30 min, sections were in-
cubated with rabbit polyclonal anti-BMP7 antibody
(1 :300 ; Abcam, USA; ab56023) overnight at 4 xC, then
for 2 h with goat polyclonal secondary antibody
to rabbit IgG-H&L (1:100, HRP; Abcam; ab6721).
For BMPRII immunoreactivity, after the blocking in-
cubation, sections were incubated with goat anti-
BMPRII antibody (1 :100 ; Santa Cruz Biotechnology,
USA; sc-5682) in 0.5 M Tris-buffered saline with
0.1% Triton-X 100 (pH 7.4) overnight at 4 xC, for 1 h
with secondary biotinylated horse anti-goat antibody
(1 :200 ; Vector Laboratories, USA; BA-9500), and then
for 1 h at 22 xC with avidin-biotinylated horseradish
peroxidase complex (Vector Laboratories).
LCM
LCM was performed on an Arcturus VeritasTM
Microdissection Instrument ; Model 704 (Molecular
Devices) as described previously (Ordway et al. 2009).
Quantitative PCR
Total RNA was isolated from laser-captured cells and
tissue homogenates, then reverse-transcribed as de-
scribed previously (Xiang et al. 2008). rtPCR was used
to quantify transcripts in RNA from tissue homo-
genates as described previously (Xiang et al. 2008).
Because of smaller amounts of RNA available, end-
point PCR was used to quantify transcripts from LCM
samples as described previously (Ordway et al. 2009).
Genes and primers are listed in Table 2.
Chronic social defeat paradigm
Chronic social defeat stress is based on the
resident–intruder paradigm as described previously
(Koolhaas et al. 1997; Miczek, 1991 ; Rygula et al. 2005),
with minor modifications. All animal procedures were
approved by the East Tennessee State University
Animal Care and Use Committee and complied with
the NIH Guide for the Care and Use of Laboratory
Animals. Male Fischer-344 rats (250–275 g) served as
the experimental ‘ intruder’ animal and Long–Evans
rats (retired male breeders weighing 350–400 g) served
as ‘residents’, residing with a sterile female rat for a
week. Exposure of intruders was repeated four times
for the first week, twice in the second and third weeks,
and four times in the fourth week. The effectiveness
of the defeat paradigm was evaluated by measuring
sucrose consumption. On day 29, animals were
euthanized and brains were dissected and frozen on
dry ice. LC tissue containing neurons, glia and
surrounding neuropil were dissected under a stereo-
microscope from frozen slide-mounted sections cut
through the brainstem at the level of the LC.
Statistical analyses
For reversed-transcribed RNA extracted from tissue
homogenates from matched depressed and control
subjects, cycle threshold (Ct) values of PCR-generated
gene transcripts were determined and normalized by
subtracting the geometric mean (Vandesompele et al.
2002) of the Ct values of reference gene expressions
generated from the identical samples. Resulting DCt
values were converted to relative gene expression in
fold changes comparing MDD subjects to control sub-
jects, using the 2xDDCt method (Livak & Schmittgen,
2001). Data from rtPCR using tissue homogenate
samples and end-point PCR analyses of the three cell
types captured by LCM were analysed by paired
Student’s t test. Data from rtPCR analyses of tissues
from social defeat rats and cage controls were
analysed using an unpaired Student’s t test. Summary
statistics are reported as the mean¡S.E.M. Possible re-
lationships between post-mortem variables and levels
of gene expression were evaluated using Pearson’s
correlation analyses. Covariate analysis of variance
was performed to determine whether demographic
variables (e.g. RIN) modified the results of the stat-
istical analyses. Statistical analyses were performed
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using GraphPad Prism 5.0 (GraphPad Software
Inc., USA) and Minitab (Minitab Inc., USA). A p value
<0.05 was considered significant.
Results
Quantitative rtPCR was used to examine BMP7 gene
expression levels in tissue punch-dissected from the
LC region in brains from MDD subjects and matched
psychiatrically normal control subjects. BMP7 gene
expression in MDD subjects was approximately one
third the level of expression in normal control subjects
(n=12 pairs ; Fig. 2 ; p=0.001). In this initial exper-
iment, ACTB (b-actin) was used as the reference gene
and tissue RNAs were exhausted from this set of
samples because other work had been performed with
these tissues. Further investigation below involved
dissection of additional LC tissue from tissue blocks of
all subjects, with three additional pairs of control and
MDD subjects replacing three pairs used above from
whom tissue was no longer available.
Given that BMP7 is one of a family of proteins, the
gene expression of other BMPs was examined using
mRNA isolated from punched-dissected LC tissue.
Since a different set of samples were used for this
further analysis, BMP7 gene expression was analysed
again to confirm the finding above. Furthermore, three
reference genes were used for this analysis ACTB,
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
and ubiquitin C (UBC) to increase the level of scrutiny
Table 2. Primer sequences of target and reference genes
Target or referencea Genbank accession number Primer sequence PCR product size (bp)
ACTB NM_001101 (f) GCACCCAGCACAATGAAGATCAAG 128
(r) TCATACTCCTGCTTGCTGATCCAC
BMP2 NM_001200 (f) GTGCGCAGCTTCCACCATGAA 122
(r) CTGAGGTGATAAACTCCTCCGTGGG
BMP4b NM_001202 (f) CCAACACCGTGAGGAGCTTCCACCA 118
NM_130850 (r) GAGATCACCTCGTTCTCAGGGATGCTGC
NM_130851
BMP5 NM_021073 (f) GCCCATATGAATGCCACCAACCAC 80
(r) CAAGGCTTTGGTACGTGGTCAGGA
BMP6 NM_001718 (f) AGCCTGCAGGAAGCATGAGCTGTA 89
(r) AATTGGCAGCATAGCCCTTGGGTG
BMP7 BC004248 (f) AACCGCTCCAAGACGCCCAAGAACCA 91
(r) TCTTACAGGCCTGCCTCTGGTCGCTG
BMP7 (rat) XM_342591 (f) AGGGAGAGTGTGCCTTCCCTCTGAACT 102
(r) GCTTGGGTACGGTGTCTGGGTTGATGA
BMP9 NM_016204 (f) GGTTCCAGAAACCTGCCCTTCTTTGT 98
(r) TCATGGCTGATCATCTCCCTCAGCTC
BMP11 NM_005811 (f) CTTTGATCCCAGTGGCACAGACCT 97
(r) TGTGTTCTCTAGGACTCGAAGCTCCA
BMPRII NM_001204 (f) ACAAATCTGTGAGCCCAACAGTCAATCC 82
(r) GGCACACGCCTATTATGTGACAGGTTG
BMPR1a NM_004329 (f) TCTACCAAACTGTGCTAATGCGCCA 84
(r) GCTGAGTCCAGGAACCTGTACCTTT
ACTR1bc NM_004302 (f) TAAGCTGGCCTTGTCTGCTGCTAGTG 92
(r) ATGCTCGATGAGCAATTCCAGGCTTCC
GAPDH NM_002046 (f) TGCACCACCAACTGCTTAGC 87
(r) GGCATGGACTGTGGTCATGAG
GAPDH (rat) AF106860 (f) CTCCCATTCTTCCACCTTTGATGCTGGG 110
(r) CCACCACCCTGTTGCTGTAGCCATATTC
UBC NM_021009 (f) ATTTGGGTCGCGGTTCTTG 133
(r) TGCCTTGACATTCTCGATGGT
aAll genes shown are human except where noted.
b BMP4 transcript variants 1, 2 and 3.
cACTR1b (ACVR1B) transcript variants 1, 2 and 3.
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of the study. Gene expression levels for BMP2, BMP4,
BMP5, BMP6, BMP9, and BMP11 genes were similar in
control and MDD subjects (Fig. 3 a). In contrast, BMP7
gene expression was significantly lower (p=0.0018,
Fig. 3 a) in MDD subjects, confirming the original
finding above in this separate set of samples.
Levels of gene expression of three receptors that
mediate BMP signalling were also investigated using
the same samples, including BMPRII, BMPR1a, and
ActR1b. These receptors were chosen (amongst
other BMP receptors) based on demonstrable gene
expression levels previously reported for the mouse
LC (Allen Brain Atlas Resources, 2009). No significant
differences in levels of BMP receptor gene expression
were found comparing normal control and MDD
subjects (Fig. 3 b).
To determine whether low BMP7 gene expression in
MDD is widespread throughout the brain, quantitat-
ive rtPCR was used to probe the expression of BMP7
in two other brain regions, prefrontal cortex (12 pairs
of control and MDD subjects) and amygdala (eight
pairs of control and MDD subjects). Not all of the
subjects used for these studies were the same as were
used for the study of LC tissues (see Supplementary
Table S1), as indicated in Table 1, because cortical and
amygdala tissues were not available for all of the same
cases. In contrast to the LC, no differences in the levels
of gene expression of BMP7 in cortical grey or white
matter were observed comparing MDD to control
subjects (Fig. 4). Similarly, no differences in BMP7
gene expression were observed in the basal nucleus of
the amygdala (Fig. 4).
To determine which cell type was responsible for
the reduced BMP7 gene expression, LCM was em-
ployed to separately capture noradrenergic neurons,
astrocytes, and oligodendrocytes from sections cut
through the LC from six pairs of normal control
and MDD subjects (Table 1). The method used to
capture each cell type has been previously validated
by examining gene expression profiles of cell-type
specific markers, i.e. tyrosine hydroxylase for nora-
drenergic neurons, glial acidic fibrillary protein
(GFAP) for astrocytes, and myelin oligodendrocyte
glycoprotein (MOG) for oligodendrocytes (Ordway
et al. 2009). Data collected were normalized to three
reference genes (GAPDH, UBC and ACTB) and also
separately to the number of cells collected (Ordway
et al. 2009). Of the three cell types, astrocytes had the
largest level of BMP7 gene expression, being nearly
4-fold higher than that in noradrenergic neurons,
whether expressed relative to reference genes (Fig. 5 a)
or relative to the number of cells captured (Fig. 5 b).























Fig. 2. Initial real-time PCR analysis of BMP7 gene
expression in punch-dissected LC tissue from 12 matched
pairs of MDD subjects (&) and psychiatrically normal
control subjects (Con, %). Relative gene expression levels
are expressed as fold changes using the method of Livak &
Schmittgen (2001). Target gene expression was normalized


































































Fig. 3. Real-time PCR analysis of the gene expression of
several BMPs (a) and associated receptors (b) in
punched-dissected locus coeruleus (LC) tissues from
12 matched MDD (&) and psychiatrically normal control
(%) subjects. Some of the subjects used in this set of
experiments were different than those used to generate data
in Fig. 2 as noted in Results. Target gene expression was
normalized with the geometric mean of three reference genes
(GAPDH, UBC and ACTB) as described in the Methods
section. Relative gene expression levels were computed as
fold changes using the method of Livak & Schmittgen (2001).
The line above the bars indicates statistical significance for
the specified comparison (p=0.0018). No other comparisons
between control and MDD subjects reached statistical
significance.
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observed in astrocytes, but not in neurons, from major
depressive subjects as compared to normal control
subjects (p=0.0058, Fig. 5 a, b). Oligodendrocytes
showed a smaller reduction in BMP7 gene expression
that was only statistically significant when gene ex-
pression levels were normalized by the number of
cells captured (p=0.042, Fig. 5 b) rather than by refer-
ence gene expressions. Given that levels of BMPRII
gene expression were highest amongst the BMP re-
ceptors studied in the LC punches above, BMPRII
gene expression was evaluated in the three cell types
captured by LCM. BMPRII gene expression was high-
est in neurons relative to the other two cell types (Fig.
5 c, d). No significant differences in BMPRII gene ex-
pression were observed in any of the three LC cell
types comparing control and MDD subjects.
BMP7 protein immunoreactivity in the LC
To determine whether BMP7 gene expression changes
were paralleled by similar protein expression changes
in the LC, we attempted to measure BMP7 immuno-
reactivity using quantitative Western blotting and
ELISA. However, the quantities of frozen LC tissue
that were required to perform these studies exceeded
available tissues. It seemed important to at least es-
tablish the presence of BMP7 protein in the region
of the LC. To do this, the general distribution of
BMP7 and BMPRII immunoreactivity in the region
of the human LC was examined using immuno-
cytochemistry of fixed human LC tissue. BMP7
immunoreactivity was apparent in glia and nor-
adrenergic neurons in the region of the LC (Fig. 6,
left panel). For BMP7, glia were darkly stained,
although stained glial processes were not obvious.
Noradrenergic neurons and proximal processes
also demonstrated BMP7 immunoreactivity. BMP7
immunoreactivity was more intensely stained in the
epithelial layer at the floor of fourth ventricle and
in cerebellar cortical neurons and glia (not shown).
BMPRII immunoreactivity was most robust in LC
neurons, with minimal staining of glia (Fig. 6, right
panel).
Consideration of potentially confounding issues
The possibility that variables unrelated to psychiatric
status contributed to gene expression differences
in the LC between the two groups of subjects was
extensively considered. For the PCR analyses of the
punched-dissected LC tissues, levels of gene ex-
pression of each reference gene in control and MDD
subjects were normalized using the other two refer-
ence genes. No significant differences were observed
comparing control and MDD subjects for GAPDH,
UBC or ACTB (Fig. 7). However, it is noteworthy that
b-actin gene expression in the LC was modestly lower
in MDD subjects relative to control subjects (p=0.059).
Given this tendency, levels of expression for all BMP
genes were recalculated using only GAPDH and UBC
for normalization. BMP7 gene expression remained
significantly lower in MDD subjects (p=0.0009; data
not shown). The results of the statistical analyses of
the other BMPs using just two reference genes were
unaffected, except for the observation of a modest
but significantly lower gene expression for BMPIIR
(p=0.01).
Levels of reference genes in laser captured cells
from the two study groups were also evaluated. Levels
of each reference gene expressed relative to the mean
of the other two were analysed for each cell type.
No differences in the levels of gene expression of
GAPDH, UBC or ACTB were observed in nora-
drenergic neurons, astrocytes or oligodendrocytes
comparing control to MDD subjects (see Supplemen-
tary Table S2, online).
MDD and normal control subjects were carefully
matched for several parameters to reduce the influ-
ence of potentially confounding issues. However, not
all variables can be matched exactly in post-mortem

























Fig. 4. Real-time PCR analysis of the gene expression of
BMP7 in frontal cortical (BA 10) and amygdala tissues from
carefully matched MDD (&) and psychiatrically normal
control (%) subjects. BMP7 gene expression was normalized
with the geometric mean of the gene expression of ubiquitin
C and TATA box binding protein (cortical tissues) or with
GAPDH (amygdala) gene expression as described in the
Methods section. Relative gene expression levels were
computed as fold changes using the method of Livak &
Schmittgen (2001). Sample sizes were 12 matched pairs of
subjects for cortical tissues and eight matched pairs of
subjects for basal amygdala.
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limitation of the availability of brain tissue from sub-
jects that meet inclusion criteria. Post-mortem inter-
vals, ages, pH values, and RNA integrity number
(RIN) values and their averages appear in Table 1.
There were no statistically significant differences
between the two study groups comparing ages, pH
values, or RIN values. The post-mortem interval (PMI)
values of MDD subjects were significantly longer
than control subjects. However, as we have observed
previously (Xiang et al. 2008), the length of the PMI
did not correlate with the quality of RNA extracted
from tissues, either for the control group (Pearson’s
r=x0.085, p=0.72), the MDD group (Pearson
r=x0.13, p=0.60), or for the combination of all con-
trol and MDD subjects (Pearson r=x0.21, p=0.19).
Also, PMI did not significantly correlate with ex-
pression levels of any of the genes studied. The longer
PMI values of the MDD subjects is typical in our hands
and is due to the fact that most of the MDD subjects
died by suicide, which in most cases is committed in
isolation making discovery of the deceased longer.
RIN values were lower than those typically observed
with fresh brain tissues from animal studies, but were
typical for post-mortem brain tissue in our hands.
There were no significant correlations between RIN
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Fig. 5. Gene expression of BMP7 and BMPIIR in neurons (N), astrocytes (A) and oligodendrocytes (O) captured by laser
capture microdissection from tissue sections cut through the locus coeruleus (LC) from six matched pairs of MDD (&) and
psychiatrically normal control (%) subjects. Target gene expression was normalized with the geometric mean of the gene
expression of GAPDH, UBC and ACTB (a, c), and was also normalized with the number of cells captured (b,d ). The lines
above the bars indicate statistical significance for the specified comparison. No other comparisons reached statistical
significance.
20 µm 20 µm
Fig. 6. Sections cut through the human locus coeruleus showing BMP7-immunoreactivity (left panel, 40r) and
BMPRII-immunoreactivity (right panel, 20r). BMP7-immunoreactivity is obvious in large noradrenergic neuronal cell
bodies (arrows) containing neuromelanin and in smaller glia (carets) in the immediate area surrounding neurons.
BMPIIR-immunoreactivity is primarily evident in the large darkly stained noradrenergic neurons.
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genes. Furthermore, the outcome of the statistical
analyses did not change when RIN was used as a
covariate. The lack of an impact of RIN values in the
range of those obtained here on PCR product amounts
is similar to that described by others (Schroeder et al.
2006), likely at least in part because primers were
deliberately designed to amplify small products,
i.e. 80–133 bases (see Table 2). Levels of PCR products
of this length are generally independent of RNA
quality (Fleige & Pfaffl, 2006).
Finally, four MDD subjects had a history of anti-
depressant drug prescriptions and two MDD subjects
died of non-suicide causes in the study of LC BMP7
gene expression. These sample sizes were too small to
evaluate statistically. Individual comparisons of BMP7
gene expression levels of MDD subjects with anti-
depressant prescriptions to their matched control
subjects revealed the following fold changes : 0.32,
0.32, 0.72, and 1.06. Hence, three out of four MDD
subjects demonstrated lower BMP7 gene expression
than their matched controls, implying no major effect
of historical antidepressant exposure on BMP7 gene
expression. Individual comparisons of BMP7 gene
expression levels of the non-suicide MDD subjects
to matched control subjects revealed fold changes
of 0.38 and 0.32, suggesting that reduced BMP7 gene
expression is not specific to suicide but observed in all
MDD subjects.
Effect of chronic stress on BMP7 gene expression
in rats
Experiments were performed to determine whether
BMP7 changes in MDD are mimicked in the rat social
defeat paradigm, a rodent stress model producing
symptoms analogous to depression in humans
(Rygula et al. 2005). Statistically significant reductions
in sucrose consumption in the defeated rats were
observed in weeks 1–4 of the paradigm (see
Supplementary Fig. S1, online) compared to the con-
trol rats, confirming the effectiveness of the defeat
paradigm. Gene expression was measured by rtPCR
using RNA isolated from homogenates of dissected
LC tissue. BMP7 gene expression was significantly
lower in defeated rats as compared to control rats
(p=0.022, Fig. 8).
Discussion
Bone morphogenetic proteins are a family of multi-
functional proteins produced by a number of different
body tissues, including the brain where they play a
major role in the developing nervous system. Besides
directing differentiation of glia (Gross et al. 1996;
Mabie et al. 1997), BMP7, like BMP5 and BMP6, pro-
mote catecholamine neurite outgrowth (Guo et al.
1998; Jordan et al. 1997). In addition, BMP7 promotes
catecholaminergic neuronal differentiation (Brederlau
et al. 2002) and disruption of BMP7 function results in
a loss of the catecholamine phenotype (Schneider et al.



























Fig. 7. Real-time PCR analysis of the expression of reference
genes used in the analyses of BMPs in punched-dissected
locus coeruleus tissues from 12 carefully matched MDD
(&) and psychiatrically normal control (%) subjects.
Each reference was normalized with the geometric mean
of the expression of the other two reference genes.
Relative gene expression levels were computed as fold
changes using the method of Livak & Schmittgen (2001).
There were no statistically significant differences, although






















Fig. 8. Real-time PCR analyses of the gene expression of
BMP7 in locus coeruleus tissue dissected from rats exposed
to social defeat (n=6) stress and cage controls (n=6). BMP7
gene expression was normalized with GAPDH gene
expression in the same tissues. Relative gene expression
levels were computed as fold changes using the method of
Livak & Schmittgen (2001). The asterisk indicates statistical
significance comparing defeated rats to control rats
(p=0.022). The social defeat paradigm was associated with
significant reductions in sucrose consumption in defeated
rats (see Supplementary Fig. S1).
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BMP7 drew our intense interest given evidence of
noradrenergic pathology in MDD (Ordway, 2007), as
well as numerous reports of deficits in other neuro-
trophic factors in MDD. The results of the present in-
vestigation revealed that the BMP7 gene is expressed
in catecholamine neurons and surrounding astrocytes
and oligodendrocytes in the human pontine brain-
stem, and its expression is significantly lower in LC
astrocytes from MDD subjects compared to matched
control subjects.
Evaluating the neurobiological impact of a BMP7
deficit in MDD is difficult because there is limited in-
formation about the regulation and function of BMP7
in the adult nervous system. Experimental stroke
models in adult rats demonstrate elevations of brain
BMP7 (Chang et al. 2003), while infusion BMP7 re-
duces infarct size (Perides et al. 1995) and enhances
recovery in stroke rats (Chang et al. 2003; Kawamata
et al. 1998). Lesions of midbrain dopamine neurons
in adult rats results in a robust reduction in the gene
expression levels of several BMPs, including BMP7,
and their receptors in the substantia nigra (Chen et al.
2003). Conversely, exogenous administration of BMP7
reduces the damaging effects of 6-hydroxydopamine
on catecholamine neuronal indices and improves
catecholamine-mediated behaviour in adult rats
(Harvey et al. 2004), demonstrating neuroprotective
and possibly neuro-reparative effects of BMP7. Col-
lectively, these studies demonstrate that BMP7 is
capable of exerting robust and important biological
effects in the adult mammalian CNS.
BMP7, as well as other related BMPs, signal through
several different heterodimeric serine/threonine
kinase receptors, including BMPIIR, BMPR1a,
BMPR1b, and activin receptors (Attisano & Wrana,
2002 ; Canalis et al. 2003). Levels of gene expression of
BMP7 and its receptors vary by brain region in the
rodent (Charytoniuk et al. 2000) and human forebrain
(Allen Brain Atlas Resources, 2009). The results pres-
ented here are the first examination of BMP7 and
BMP receptor gene and/or protein expression in the
human pontine region, including the LC, and demon-
strate that both neurons and glia in the brainstem
express BMP7. BMPRII gene expression was robust
in human LC neurons, consistent with levels
reported previously in mouse LC (Allen Brain Atlas
Resources, 2009) BMP receptor gene expression
showed a tendency for reduced levels in MDD sub-
jects, but further study of BMP receptors and signal-
ling pathways in MDD is needed before firm
conclusions can be made.
Although the present study is the first to dem-
onstrate a potential role of BMPs in MDD, there are
other studies demonstrating an association of BMP or
BMP-related signalling molecules with antidepressant
drug action. Phosphorylated Smad proteins, intra-
cellular mediators of activated BMP receptors, are
upregulated by repeated treatment of rats with anti-
depressant drugs (Dow et al. 2005). Also, direct in-
fusion of activin, which activates some of the same
receptors as BMPs, into the hippocampus produces an
antidepressant behavioural response (Dow et al. 2005).
These findings suggest that increasing BMP signaling
may have antidepressant effects. Interestingly, a single
nucleotide polymorphism upstream of the BMP7 gene
has been reported to be less frequent in subjects as-
sociated with response and remission following
administration of the antidepressant citalopram
(Garriock et al. 2010). Four of the 16 MDD subjects for
whom the LC was studied presently had been pre-
scribed antidepressants sometime prior to committing
suicide. If the BMP7 polymorphism is associated
with reduced promoter activity and thereby reduced
BMP7 gene expression, then it is intriguing to specu-
late that this polymorphism could ultimately contrib-
ute to suicide because of a lack of antidepressant
efficacy.
Several neurochemical and morphological patho-
logies of the LC from major depressive subjects or
victims of suicide have been described previously.
These include abnormalities in levels of several nor-
adrenergic proteins, altered levels of proteins reflect-
ing regulatory inputs to the LC, and abnormalities in
neuronal morphology (Bernard et al. 2011; Gos et al.
2008; Shibata et al. 2007, 2008 ; see Ordway, 2007). The
present study extends these previous observations to
glial pathology in the region of the LC. Pathologies of
glia (Bowley et al. 2002; Cotter et al. 2001; Fatemi et al.
2004; Ongur et al. 1998; Rajkowska et al. 1999; Uranova
et al. 2004) have been demonstrated previously in
several brain regions, but the present study is the first
to demonstrate specific involvement of astrocyte
pathology in the brainstem, in particular low levels
BMP7 in LC astrocytes in MDD subjects. It is interest-
ing that glia-derived BMP7 stimulates dendritic
growth in co-cultures of noradrenergic neurons and
glia (Lein et al. 2002b). Based on the cellular distri-
bution of BMP7 and at least one of its receptors
(BMPIIR) as demonstrated here for the human LC, it is
conceivable that BMP7 liberated from astrocytes that
are in close proximity to LC neuronal dendrites serves
a paracrine role in the maintenance or growth of LC
neuronal dendrites. If like BMP7 gene expression,
BMP7 protein levels are low in MDD subjects,
then deficient glia-derived trophic support to nor-
adrenergic LC neurons may result.
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There are a number of weaknesses of the present
study. A majority (n=16) of the 19 MDD subjects died
by suicide. With such a small number of non-suicide
MDD subjects, it was not possible to statistically ana-
lyse the potential confounding effect of suicide on the
data. Although it is intriguing to consider the possi-
bility that reduced BMP7 gene expression in MDD
is accompanied by a reduction in BMP7 protein, a re-
duction in protein does not always parallel less gene
expression. Unfortunately, attempts to measure BMP7
protein in frozen human LC failed. BMP7 gene ex-
pression changes were not observed in homogenates
of the prefrontal cortex or in the basal nucleus of the
amygdala. It is possible that a change in BMP7 gene
expression was missed because gene expression was
not analysed at the level of single cell types in these
two brain regions. However, it is worth noting that
reduced BMP7 gene expression was observed in the
LC in both homogenates of LC tissue as well as in
LCM-captured LC astrocytes. BMP7 gene expression
may be reduced in other regions not explored as well,
such as in other brainstem catecholamine cell groups.
The action of BMPs is modulated by a number of ex-
tracellular proteins that sequester BMPs and thereby
inhibit their action at BMP receptors. These include
noggin, follistatin, chordin and other cysteine knot
proteins (Canalis et al. 2003). These additional targets
need to be studied to gain a complete understanding
of BMP signalling alterations in MDD.
Low levels of BMP7 gene expression in LC astro-
cytes may contribute to noradrenergic neuronal path-
ology that has been previously associated with MDD.
It is equally possible that pathology of noradrenergic
signaling within the LC may contribute to local glial
dysfunction, since astrocytes express receptors for
norepinephrine and respond to norepinephrine sig-
naling (Bekar et al. 2008; Hertz et al. 2004; Porter &
McCarthy, 1997). Translating these clinical findings
will require basic studies to elucidate how BMP7 gene
expression is regulated, and how BMP7 regulates
the function of adult noradrenergic neurons. Initial
studies here demonstrate that social defeat stress in
rats produces a reduction in BMP7 gene expression in
the LC. Based on the known actions of BMP7, it seems
possible that a stress-induced reduction in BMP7
could contribute detrimentally to other catechol-
aminergic disruptions that accompany chronic stress
and depression (Ordway, 2007; Ordway et al. 2002).
Previous studies (Harvey et al. 2004, 2005) have im-
plicated potential therapeutic utilities of BMP7 in
neurodegenerative disorders and traumatic brain in-
jury. The present study suggests that BMP7 plays a role
in the catecholamine pathology of major depression
and implies that therapeutic strategies to increase
BMP7 signalling may have pro-antidepressant effects.
Note
Supplementary material accompanies this paper on
the Journal’s website (http://journals.cambridge.org/
pnp).
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